Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction

Cancer

Volumn 97, Issue 11, 2003, Pages 2887-2897

  Tsang, Kam Sze ^a   Li, Chi Kong ^a   Tsoi, Wai Chiu ^a   Leung, Yonna ^a   Shing, Matthew Ming Kong ^a   Chik, Ki Wai ^a   Lee, Vincent ^a   Ng, Margaret Heung Ling ^a   Yuen, Patrick Man Pan ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Flow cytometry; Hematopoietic stem cells; Neuroblastoma; Reverse transcriptase polymerase chain reaction (RT PCR); Tyrosine hydroxylase

Indexed keywords

CD34 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD81 ANTIGEN; TYROSINE 3 MONOOXYGENASE;

ARTICLE; AUTOGRAFT; BONE MARROW BIOPSY; BONE MARROW METASTASIS; BONE MARROW TRANSPLANTATION; CANCER DIAGNOSIS; CANCER STAGING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN TISSUE; MALE; NEUROBLASTOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, CD; ANTIGENS, CD45; ANTIGENS, CD56; BONE MARROW; BONE MARROW TRANSPLANTATION; CHILD; FLOW CYTOMETRY; HUMANS; MEMBRANE PROTEINS; NEOPLASM METASTASIS; NEUROBLASTOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, AUTOLOGOUS; TYROSINE 3-MONOOXYGENASE;

EID: 0038182640     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11389     Document Type: Article

References (52)

1. Evans AE. Neuroblastoma: a historical perspective. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA, editors. Neuroblastoma. Amsterdam: Elsevier Science BV, 2000:1-19.
2. Castleberry RP, Pritchard J, Ambros P, et al. The International Neuroblastoma Risk Groups (INRG): a preliminary report. Eur J Cancer. 1997;33:2113-2116.
3. Castleberry RP. Consistently investigating the inconsistent nature of neuroblastoma. J Pediatr Hematol Oncol. 1999;21: 178-180.
4. Evans AE, D'Angio GJ, Propert K, Anderson J, Hann HW. Prognostic factor in neuroblastoma. Cancer. 1987:59:1853-1859.
5. Moss TL Reynolds CP, Sather HN, Romansky SG, Hammond GD, Seeger RC. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med. 1991;324:219-226.
6. Cheung NK, Heller G, Kushner BH, Liu C, Cheung IY. Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive? J Clin Oncol. 1997; 15:2807-2817.
7. Atra A, Pinkerton R. Autologous stem cell transplantation in solid tumours of childhood. Ann Med. 1996;28:159-164.
8. Shuster JJ. The role of autologous bone marrow transplantation in advanced neuroblastoma. J Clin Oncol. 1996;14: 2413-2414.
9. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis- retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165-1173.
10. Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993;341:85-86.
11. Rill DR, Santana VM, Roberts WM, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood. 1994;84:380-383.
12. Deisseroth AB, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 1994;83:3068-3076.
13. Heslop HE, Rooney CM, Rill DR, Krance RA, Brenner MK. Use of gene marking in bone marrow transplantation. Cancer Detect Prev. 1996;20:108-113.
14. Handgretinger R, Lang P, Ihm K, et al. Isolation and transplantation of highly purified autologous peripheral CD34(+) progenitor cells: purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma. Bone Marrow Transplant. 2002;29:731-736.
15. Burchill SA, Lewis IJ, Abrams KR, et al. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol. 2001;19:1795-1801.
16. Lo Piccolo MS, Cheung NK, Cheung IY. GD2 synthase: a new molecular marker for detecting neuroblastoma. Cancer. 2001;92:924-931.
17. Corrias MV, Scaruffi P, Occhino M, De Bernardi B, Tonini GP, Pistoia V. Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma. Int J Cancer. 1996;69:403-407.
18. Cheung IY, Cheung NK. Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma. Clin Cancer Res. 1997;3: 821-826.
19. Komada Y, Zhang XL, Zhou YW, et al. Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma. Cancer. 1998;82:591-599.
20. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-1477.
21. Lee V, Li CK, Shing MM, et al. Single vs twice daily G-CSF dose for peripheral blood stem cells harvest in normal donors and children with non-malignant diseases. Bone Marrow Transplant. 2000;25:931-935.
22. Burchill SA, Bradbury FM, Smith B, Lewis IJ, Selby P. Neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. Int J Cancer. 1994;57:671-675.
23. Nagai J, Ishida Y, Koga N, et al. A new sensitive and specific combination of CD81/CD56/CD45 monoclonal antibodies for detecting circulating neuroblastoma cells in peripheral blood using flow cytometry. J Pediatr Hematol Oncol. 2000; 22:20-26.
24. Tsang KS, Li CK, Wong AP, et al. Processing of major ABO-incompatible bone marrow for transplantation by using dextran sedimentation. Transfusion. 1999;39:1212-1219.
25. Faulkner LB, Tintori V, Tamburini A, et al. High-sensitivity immunocytologic analysis of neuroblastoma cells in paired blood and marrow samples. J Hematother. 1998;7:361-366.
26. Kashima T, Tiu SN, Merrill JE, Vinters HV, Dawson G, Campagnoni AT. Expression of oligodendrocyte-associated genes in cell lines derived from human gliomas and neuroblastomas. Cancer Res. 1993;53:170-175.
27. Mattano LA Jr., Moss TJ, Emerson SG. Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction. Cancer Res. 1992;52: 4701-4705.
28. Miyajima Y, Kato K, Numata S, Kudo K, Horibe K. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer. 1995; 75:2757-2761.
29. Hoon DS, Kuo CT, Wen S, et al. Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow. Am J Pathol. 2001;159: 493-500.
30. Evans AE, Hummeler K. The significance of primitive cells in marrow aspirates of children with neuroblastoma. Cancer. 1973;32:906-912.
31. Gilbert J, Norris MD, Marshall GM, Haber M. Low specificity of PGP9.5 expression for detection of micrometastatic neuroblastoma. Br J Cancer. 1997;75:1779-1781.
32. Ishida H, Matsumura T, Salgaller ML, Ohmizono Y, Kadono Y, Sawada T. MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors. Int J Cancer. 1996;69:375-380.
33. Cheung IY, Cheung NK. Detection of microscopic disease: comparing histology, immunocytology, and RT-PCR of tyrosine hydroxylase, GAGE, and MAGE. Med Pediatr Oncol. 2001;36:210-212.
34. Ponthan F, Borgstrom P, Hassan M, Wassberg E, Redfern CP, Kogner P. The vitamin A analogues: 13-cis retinoic acid, 9-cis retinoic acid, and Ro 13-6307 inhibit neuroblastoma tumour growth in vivo. Med Pediatr Oncol. 2001;36:127-131.
35. Reynolds CP, Lemons RS. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am. 2001;15:867-910.
36. Singh IN, Sorrentino G, McCartney DG, Massarelli R, Kanfer JN. Enzymatic activities during differentiation of the human neuroblastoma cells, LA-N-1 and LA-N-2. J Neurosci Res. 1990;25:476-485.
37. Bryson GJ, Lear D, Williamson R, Wong RC. Detection of the CD56+/CD45-immunophenotype by flow cytometry in neuroendocrine malignancies. J Clin Pathol. 2002;55:535-537.
38. Oren R, Takahashi S, Doss C, Levy R, Levy S. TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol. 1990;10:4007-4015.
39. Lipinski M, Hirsch MR, Deagostini-Bazin H, Yamada O, Tursz T, Goridis C. Characterization of neural cell adhesion molecules (NCAM) expressed by Ewing and neuroblastoma cell lines. Int J Cancer. 1987;40:81-86.
40. Chang TK, Li CY, Smithson WA. Immunocytochemical study of small round cell tumors in routinely processed specimens. Arch Pathol Lab Med. 1989;113:1343-1348.
41. Brahmi U, Rajwanshi A, Joshi K, et al. Flow cytometric immunophenotyping and comparison with immunocytochemistry in small round cell tumors. Anal Quant Cytol Histol. 2001;23:405-412.
42. Chan KW, Petropoulos D, Choroszy M, et al. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors. Bone Marrow Transplant. 1997;20:1039-1043.
43. Combaret V, Favrot MC, Kremens B, et al. Immunological detection of neuroblastoma cells in bone marrow harvested for autologous transplantation. Br J Cancer. 1989;59:844-847.
44. Moss TJ, Sanders DG, Lasky LC, Bostrom B. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood. 1990;76:1879-1883.
45. Dominici C, Deb G, Angioni A, et al. Peripheral blood stem cells in children with solid tumors. Part II. Immunocytologic detection of tumor cells in bone marrow and peripheral blood stem cell harvests. Anticancer Res. 1993;13:2573-2575.
46. Leung W, Chen AR, Klann RC, et al. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant. 1998;22:971-979.
47. Tchirkov A, Kanold J, Combaret V, et al. Immunological and molecular detection of tumor contamination in leukapheresis products from children with disseminated neuroblastoma: implication for evaluation of tumor cell depletion after CD34 selection. Bone Marrow Transplant. 1999;24:229-230.
48. Burchill SA, Kinsey SE, Picton S, et al. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. Med Pediatr Oncol. 2001;36:213-219.
49. Bachier CR, Giles RE, Ellerson D, et al. Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. Leuk Lymphoma. 1999;32:279-288.
50. Voigt A, Hafer R, Gruhn B, Zintl F. Expression of CD34 and other haematopoietic antigens on neuroblastoma cells: consequences for autologous bone marrow and peripheral blood stem cell transplantation. J Neuroimmunol. 1997;78: 117-126.
51. Hafer R, Voigt A, Gruhn B, Zintl F. Neuroblastoma cells can express the hematopoietic progenitor cell antigen CD34 as detected at surface protein and mRNA level. J Neuroimmunol. 1999;96:201-206.
52. Dotsch J, Repp R, Rascher W, Christiansen H. Diagnostic and scientific applications of TaqMan real-time PCR in neuroblastomas. Expert Rev Mol Diagn. 2001;1:233-238.